论文部分内容阅读
多伦多消息:另一种β-阻滞剂已加入心得安用于实验性预防治疗偏头痛的行列,初步的研究表明,至少可以说是有效的。在此地举行的美国头痛研究协会会议上,圣·路易斯大学耳鼻喉科学教授Robert Ryan阐述β-阻滞剂萘羟心安(Nadolol)是预防性治疗偏头痛的一种十分有效的药物。 Ryan报告了一项为期2年的双盲随机安慰剂对照试验资料。他说,关于此试验的主要消息是萘羟心安能使一般性和典型偏头痛的疼痛次数和严重性减少一半以上。此项研究包括80例每月至少发生三次头痛的病人。20人为安慰剂组,其余60人为积极药物治疗组。治疗组中有16人中途退出试验(大多数是由于此药治疗无效),剩下总数44人完
TORONTO, Calif. - Another beta-blocker has been added to the list of experimental prophylaxis and treatment of migraine headaches, and preliminary studies have shown that, to say the least, effective. At the American Society of Headache Research conference here, Robert Ryan, professor of otolaryngology at St. Louis University, described the β-blocker Nadolol as a very potent drug for the prophylactic treatment of migraine. Ryan reports a two-year, double-blind randomized placebo-controlled trial. The main message about this trial, he said, is that naproxen can reduce the number and severity of pain in both general and typical migraine by more than half. The study included 80 patients who had at least three headaches a month. 20 for the placebo group, and the remaining 60 were active drug treatment group. Sixteen of the patients in the treatment group dropped out of the test midway (mostly due to ineffective treatment), leaving a total of 44